Proliferation News and Research

RSS

Large human islet study reveals new insights into diabetes risk

Diabetes is the most common and serious chronic disease worldwide, characterized by insufficient insulin to maintain proper blood glucose levels.

12 May 2026

Tumors exploit peripheral nerves to support cancer growth and spread

Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor microenvironment in ways that support growth, invasion, immune escape, and therapeutic resistance.

10 May 2026

Kyoto University identifies a key regulator of insulin production

A hallmark of Type 2 diabetes is the progressive loss of beta cell mass: cells in the pancreas that produce and release insulin. The endoplasmic reticulum stress response, a cellular pathway that maintains protein homeostasis, plays a critical role in beta cell function and survival, and the protein ATF6α is one of the key regulators of this stress response.

7 May 2026

Genetic background shapes outcomes in chromosome 16 deletion disorders

Individuals that share the same deletion of a portion of chromosome 16 are at risk of developing neurodevelopmental disorders, but some experience severe intellectual disability or developmental delay, while others may only exhibit milder psychiatric features like depression or anxiety.

5 May 2026

YAP1 expression drives chemotherapy resistance in small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 protein only after treatment with chemotherapy, allowing them to survive by becoming more invasive and leading to treatment resistance with eventual relapse in patients with small cell lung cancer (SCLC).

5 May 2026

New insights into ALS progression through glial cell behavior

All the core facilities of the Cibio Department of the University of Trento are involved in a study on ALS, co-funded by Fondazione AriSla, national organizations and various donors, to better understand the molecular mechanisms of slow-progressing cases.

5 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Pathogens drive inflammation by reprogramming host cell metabolic processes

An intestinal pathogen reshapes the gut environment to fuel its own colonization and cause diseases, a multi-institutional team including researchers at Vanderbilt Health has discovered.

30 Apr 2026

Glucose acts as a metabolic signal for myelin development

Researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have uncovered a surprising link between low brain sugar levels and the development of myelin - the protective coating that allows nerve cells to communicate rapidly and efficiently.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026

Biliary epithelial cells found to actively prevent liver fibrosis development

Many liver diseases share a common characteristic: fibrosis, that is, the progressive accumulation of scarring in the liver tissue.

28 Apr 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

The heart's constant beating suppresses tumor growth in cardiac tissues

The heart's constant beating may actively suppress tumor growth in cardiac tissues, a new study reports. This is because cellular pathways in these tissues alter gene regulation in cancer cells to keep them from proliferating.

25 Apr 2026

Exploiting a new weakness in 'zombie-like' cells to treat senescence-associated diseases

A new set of drugs exploit a recently-revealed weakness in 'zombie-like' – or senescent – cells that could lead to new treatments for cancer and age-associated diseases.

24 Apr 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026

Cancer-linked mutations in the brain cells may drive Alzheimer’s disease

As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's Hospital, published in Cell, finds that the brain's resident immune cells, microglia, amass mutations in specific cancer-driving genes yet they don't manifest as cancer.

21 Apr 2026

APC-deficient cancer cells rely on single enzyme for survival

A newly published study reports that APC-deficient cancer cells may depend on a single metabolic enzyme for survival, revealing a potential strategy for selectively targeting tumours associated with one of the most common mutations in colorectal cancer.

20 Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026